



Waived Co-payments

Co-payments for the diabetes-related prescription drugs and lab tests listed below are waived for Face to Face Diabetes Program participants. **However, participants are responsible for their deductibles and any cost difference in the brand and generic if the participant or physician chooses a brand where there is a generic available. In addition, some medications have an ancillary fee for which participants are responsible.** This waiver is for retail purchases only, mail order purchases are excluded. PEIA will pay 100% of PEIA's allowance for in-network services. Out-of-network services are processed at the out-of-network benefit level.

Prescription Drugs

(generics in lower case, BRANDS in upper case)

acarbose
 ACTOPLUS MET XR [ST]
 BYDUREON [ST]
 BYETTA [ST]
 glimepiride
 glipizide, er, xl
 glipizide-metformin
 GLUCAGEN
 GLUCAGON
 glyburide, micro
 glyburide-metformin
 HUMALOG
 HUMULIN

INVOKANA
 JANUMET, XR [ST]
 JANUVIA [ST]
 JENTADUETO [ST]
 JUVISYNC [ST]
 LANTUS
 LANTUS SOLOSTAR
 LEVEMIR, FLEXPEN
 metformin, er
 nateglinide
 pioglitazone
 pioglitazone-glimepiride
 pioglitazone-metformin

PROGLYCEM
 RIOMET
 SYMLIN, SYMLINPEN
 tolazamide
 tolbutamide
 TRADJENTA [ST]

[PA]: Prior Authorization required
[ST]: Step Therapy required

Rev. 1/1/14

LAB Tests

Description

Cholesterol, serum or whole blood, total
 Creatinine, blood
 Creatinine, clearance
 Creatinine, other source
 Fasting Lipid Profile
 Glucose on home meter type device
 Glucose, quantitative blood type
 HbA1c
 Lipoprotein
 Thyroid hormone (T3 or T4) update
 Thyroxine stimulating hormone (TSH)
 Thyroxine; total
 Triglycerides
 Urine, microalbumin, semiquantitative